Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation: Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine
暂无分享,去创建一个
Andrew C. Zygmunt | Charles Antzelevitch | J. M. Di Diego | C. Antzelevitch | L. Belardinelli | A. Burashnikov | Luiz Belardinelli | Alexander Burashnikov | A. Zygmunt | José M. Di Diego
[1] T. Colatsky,et al. Effects of WAY-123,398, a New Class III Antiarrhythmic Agent, on Cardiac Refractoriness and Ventricular Fibrillation Threshold in Anesthetized Dogs: A Comparison with UK-68798, E-4031, and dl-Sotalol , 1992, Journal of cardiovascular pharmacology.
[2] C. Lau,et al. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. , 2002, Journal of molecular and cellular cardiology.
[3] CHARLES ANTZELEVITCH,et al. The M Cell: , 1999, Journal of cardiovascular electrophysiology.
[4] E. Stevens,et al. The sodium channel β‐subunit SCN3b modulates the kinetics of SCN5a and is expressed heterogeneously in sheep heart , 2001, The Journal of physiology.
[5] R. Lemmens‐Gruber,et al. Electrophysiological properties of the propafenone-analogue GE 68 (1-[3-(phenylethyl)-2-benzofuryl]-2-(propylamino)-ethanol) in isolated preparations and ventricular myocytes of guinea-pig hearts , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[6] S. Nattel,et al. Characterization of the In Vivo and In Vitro Electrophysiological Effects of the Novel Antiarrhythmic Agent AZD7009 in Atrial and Ventricular Tissue of the Dog , 2006, Journal of cardiovascular pharmacology.
[7] S. Nattel,et al. Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs : potential relevance to ionic mechanisms in vivo. , 2000, Circulation.
[8] C. Antzelevitch,et al. Role of Repolarization Restitution in the Development of Coarse and Fine Atrial Fibrillation in the Isolated Canine Right Atria , 2005, Journal of cardiovascular electrophysiology.
[9] R. Kumar,et al. Determinants of action potential initiation in isolated rabbit atrial and ventricular myocytes. , 1998, American journal of physiology. Heart and circulatory physiology.
[10] J. M. Di Diego,et al. Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent , 2004, Journal of cardiovascular pharmacology and therapeutics.
[11] Charles Antzelevitch,et al. Reinduction of Atrial Fibrillation Immediately After Termination of the Arrhythmia Is Mediated by Late Phase 3 Early Afterdepolarization–Induced Triggered Activity , 2003, Circulation.
[12] U Schotten,et al. “Early” Class III Drugs for the Treatment of Atrial Fibrillation: Efficacy and Atrial Selectivity of AVE0118 in Remodeled Atria of the Goat , 2004, Circulation.
[13] C. Antzelevitch,et al. Electrophysiological Mechanisms Underlying Rate‐Dependent Changes of Refractoriness in Normal and Segmentally Depressed Canine Purkinje Fibers: The Characteristics of Post‐Repolarization Refractoriness , 1986, Circulation research.
[14] D H Singer,et al. An analysis of lidocaine block of sodium current in isolated human atrial and ventricular myocytes. , 1995, Journal of molecular and cellular cardiology.
[15] B. Chaitman. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. , 2006, Circulation.
[16] C. Antzelevitch,et al. Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. , 2004, American journal of physiology. Heart and circulatory physiology.
[17] W. Rogers,et al. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.
[18] A. Grant,et al. Basic Concepts in Cellular Cardiac Electrophysiology: Part II: Block of Ion Channels by Antiarrhythmic Drugs , 1995, Pacing and clinical electrophysiology : PACE.
[19] Hani N Sabbah,et al. Ranolazine Improves Abnormal Repolarization and Contraction in Left Ventricular Myocytes of Dogs with Heart Failure by Inhibiting Late Sodium Current , 2006, Journal of cardiovascular electrophysiology.
[20] Andrew C. Zygmunt,et al. Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.
[21] A. Waldo,et al. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. , 2004, Journal of cardiovascular electrophysiology.
[22] C. Antzelevitch,et al. Antiarrhythmic Effects of Ranolazine in a Guinea Pig in Vitro Model of Long-QT Syndrome , 2004, Journal of Pharmacology and Experimental Therapeutics.